Insights on the structural characteristics of Vim-TBS (58-81) peptide for future applications as a cell penetrating peptide

BioScience Trends

Volumn 7, Issue 5, 2013, Pages 209-220

  Saini, Avneet ^a   Jaswal, Radhika R ^a   Negi, Riteshwari ^a   Nandel, Fateh S ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

CPPs; Molecular dynamics; Molecular mechanics; P10; Peptides; Tat; Vim TBS

Indexed keywords

CELL PENETRATING PEPTIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; PEPTIDE;

ARTICLE; CHEMISTRY; MOLECULAR DYNAMICS;

CELL-PENETRATING PEPTIDES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; MOLECULAR DYNAMICS SIMULATION; PEPTIDES;

EID: 84888418773     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.5.209     Document Type: Article

References (67)

1. Lindgren M, Hallbrink M, Prochiantz A, Langel U. Cell-penetrating peptides. Trends Pharmacol Sci. 2000; 21:99-103.
2. Fatemeh M, Lindberg S, Langel U, Futaki S, Graslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys. 2011; 2011:1-10.
3. Trabulo S, Resina S, Simoes S, Lebleu B, Lima PMC. A non-covalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. Mol Ther Nucleic Acids. 2010; 145:149-158.
4. Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: Application in vaccine delivery. Biochim Biophys Acta. 2010; 1805:25-34.
5. Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev. 2009; 61:704-709.
6. Foged C, HM Nielsen. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv. 2008; 5:105-117.
7. Grdisa M. The delivery of biologically active (therapeutic) peptides and proteins into cells. Curr Med Chem. 2011; 18:1373-1379.
8. Jafari M, Chen P. Peptide mediated siRNA delivery. Curr Top Med Chem. 2009; 9:1088-1097.
9. Johnson RM, Harrison SD, Maclean D. Therapeutic applications of cell-penetrating peptides. Methods Mol Biol. 2011; 683:535-551.
10. Stewart KM, Horton KL, Kelley SO. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem. 2008; 6:2242-2255.
11. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Biopolymers 2008; 90:604-610.
12. Snyder EL, Dowdy SF. Cell penetrating peptides in drug delivery. Pharmaceutical Research. 2004; 21:3.
13. Niesner U, Halin C, Lozzi L, Gunthert M, Neri P, Wundern-Allenspach H, Zardi L, Neri D. Quantitation of the tumor-targeting properties of antibody fragments conjugated to cell-permeating HIV-1 TAT peptides. Bioconjug Chem. 2002; 13:729-736.
14. Astriab-Fisher A, Sergueev D, Fisher M, Shaw BR, Juliano RL. Conjugates of antisense oligonulceosides with the Tat and antenapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res. 2002; 19:744-754.
15. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos-Stenberg B, D'Souza GC. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA. 2003; 100:1972-1977.
16. Herce, HD, Garcia AE. Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA. 2007; 104:20805-20810.
17. Kersemans V, Kersemans K, Comelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des. 2008; 14:2415-2447.
18. Zorko M, Langel U. Cell-penetrating peptides: Mechanism and kinetics of cargo delivery. Adv Drug Del Reviews. 2005; 57:529-545.
19. Eiríksdóttir E, Konate K, Langel U, Divita G, Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta. 2010; 1798:1119-1128.
20. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001; 19:1173-1176.
21. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev. 2007; 59:134-140.
22. Coulombe PA, Wong P. Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nature Cell Biol. 2004; 6:699-706.
23. Raphael B, Julien B, Peterson AC, Eyer J. The vimentin-tubulin binding site peptide (Vim-TBS.58-81) crosses the plasma membrane and enters the nuclei of human glioma cells. Int J Pharma. 2011; 423:77-83.
24. Richard JP, Melikov K, Vives E, Ramos C, Verbuere B, Gait MJ, Chernomordik LV, Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem. 2003; 278:585-590.
25. Balzeau J, Peterson A, Eyer J. The vimentin-tubulin binding site peptide (Vim-TBS.58-81) crosses the plasma membrane and enters the nuclei of human glioma cells. Int J Pharm. 2012; 4:77-83.
26. Baker RD, Howl J, Nicholl ID. A sychnological cell penetrating peptide mimic of p21 (WAF1/CIP1) is pro-apoptogenic. Peptides 2007; 28:731-740.
27. Mutoh M, Lung FD, Long YQ, Roller PP, Sikorski RS, Connor PMO. A p21(Waf1/Cip1) carboxyl-terminal peptide exhibited cyclin-dependent kinase-inhibitory activity and cytotoxicity when introduced into human cells. Cancer Res. 1999; 59:3480-3488.
28. Warbrick E, Lane DP, Glover DM, Cox LS. A small peptide inhibitor of DNA-replication defines the site of interaction between the cyclin-dependant kinase inhibitor p21(WAF1) and proliferating cell nuclear antigen. Curr Biol. 1995; 5:275-282.
29. Jones AT. Protein secondary structure prediction based on position-specific scoring matrices. J Mol Biol. 1999; 292:195-202.
30. Johansson MU, Zoete V, Michielin O, Guex N. Defining and searching for structural motifs using DeepView/Swiss-PdbViewer. BMC Bioinformatics. 2012; 13:173.
31. Van der Spoel D, Lindahl E, Hess B, van Buuren AR, Apol E, MeulenhoffPJ, Tieleman DP, Sijbers ALTM, Feenstra KA, Van Drunen R, Berendsen HJC. Gromacs User Manual version 3.3, 2005.
32. Berendsen HJC, Postma JPM, Van Gunsteren WF, Hermans J. Intermolecular Forces: Interaction models for water in relation to protein hydration. D. Reidel Publishing Company, Dordrecht, 1981; 331-342.
33. Hockney RW, Eastwood JW. Computer simulation using particles. McGraw-Hill, New York, USA, 1981.
34. Berendsen HJC, Postma JPM, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984; 81:3684-3690.
35. Hess B, Bekker H, Berendsen HJC, Fraaije JGEM. A linear constraint solver for molecular simulations. J Comp Chem. 1997; 18:1463-1472.
36. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG. A smooth particle mesh Ewald method. J Chem Phys. 1995; 103:8577-8592.
37. Humphrey W, Dalke A, Schulten K. VMD-Visual Molecular Dynamics. J Molec Graphics. 1996; 14:33-38.
38. Nandel FS, Saini A. Peptoids with aliphatic sidechains as helical structures without hydrogen bonds and collagen/inverse-collagen type structures. Journal of Biophysical Chemistry 2011; 2:37-48.
39. Nandel FS, Saini A. Construction and design of single stranded collagen-like structure. Indian journal of biochemistry & biophysics. 2007; 44:106-113.
40. Nandel FS, Saini A. Conformational study of short peptoid models for future applications as potent antimicrobial compounds. Macromolecular Theory and Simulations. 2007; 16:295-303.
41. Alias M, Ayuso-Tejedor S, Fernandez-Recio J, Cativiela C, Sancho J. Helix propensities of conformationally restricted amino acids. Non-natural substitutes for helix breaking proline and helix forming alanine. Org Biomol Chem. 2010; 8:788-792.
42. Voet D, Voet JG, Pratt CW. Fundamentals of Biochemistry. John Wiley and Sons, New York, 2004.
43. Gunasekaran K, Nagarajaram HA, Ramakrishnan C, Balaram P. Stereochemical Punctuation Marks in Protein Structures: Glycine and Proline Containing Helix Stop Signals. J Mol Biol. 1998; 275:917-932.
44. Nandel FS, Jaswal R. New Type of Helix and 27 Ribbon Structure Formation in Poly ΔLeu Peptides: Construction of a Single-Handed Template. Biomacromolecules. 2007; 8:3093-3101.
45. Niidome T, Takaji K, Urakawa M, Ohmori N, Wada A, Hirayama T, Aoyagi H. Chain length of cationic α-helical peptide sufficient for gene delivery into cells. Bioconjugate chemistry. 1999; 10:773-780.
46. Hilda C, Arellano A. Secondary structure prediction of protamines. Int J Biol Macromol. 1982; 1:3-8.
47. Aduzbei AA, Sternberg JE. Left-handed polyproline II helices commonly occur in globular proteins. J Mol Biol. 1993; 229:472-493.
48. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem. 1997; 272:16010-16017.
49. Mujeeb A, Bishop K, Peterlin BM, Turck C, Parslow TG, James TL. NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat. Proc Natl Acad Sci U S A. 1994; 91:8248-8252.
50. Ambriz-Rivas M, Pastor N, Rio GD. Relating Protein Structure and Function Through a Bijection and Its Implications on Protein Structure Prediction. Protein Interactions. Dr. Jianfeng Cai (Ed.), 2012; ISBN: 978-953-51-0244-1.
51. Mirsky AE, Pauling L. On the structure of native, denatured, and coagulated proteins. Proc Natl Acad Sci U S A. 1936; 22:439-447.
52. Nemethy G, Peer WJ, Scheraga HA. Effect of Protein-Solvent Interactions on Protein Conformation Annual Review of Biophysics and Bioengineering 1981; 10: 459-497.
53. Mitchell JBO, Price SL. The nature of the N-H O=C hydrogen bond-- An intermolecular perturbation-theory study of the formamide formaldehyde complex. J Comp Chem. 1990; 11: 1217-1233.
54. BenTal N, SitkoffD, Topol IA, Yang AS, Burt SK, Honig B. Free energy of amide hydrogen bond formation in vacuum, in water, and in liquid alkane solution. J Phys Chem B 1997; 101: 450-457.
55. Miranda LP, Alewood PF. Chemistry-Accelerated chemical synthesis of peptides and small proteins. Proc Natl Acad Sci USA 1999; 96: 1181-1186.
56. Yongchao S, Alan JW, Ruchala P, Hong M. Membrane-bound dynamic structure of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV Tat, from solid-state NMR. Biochemistry 2010; 49:6009-6020.
57. McQueen P, Donald LJ, Vo TN, Nguyen DH, Griffiths H, Shojania S, Standing KG, O'Neil JD. Tat peptide-calmodulin binding studies and bioinformatics of HIV-1 protein-calmodulin interactions. Proteins. 2011; 79:2233-2246.
58. Shojania S, O'Neil JD. HIV-1 Tat is a natively unfolded protein: the solution conformation and dynamics of reduced HIV-1 Tat-(1-72) by NMR spectroscopy. J Biol Chem. 2006; 281:8347-8356.
59. Gunasekaran K, Tsai CJ, Kumar S, Zanuy D, Nussinov R. Extended disordered proteins: targeting function with less scaffold. Trends Biochem Sci. 2003; 28:81-85.
60. Dennison SR, Baker RD, Nicholl ID, Phoenix DAInteractions of cell penetrating peptide Tat with model membranes: A biophysical study. Biochemical and Biophysical Research Communications. 2007; 363:178-182.
61. Tunnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J. 2006; 20:1775-1784.
62. Puglisi JD, Tan R, Calnan BJ, Frankel AD, Williamson JR. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science. 1992; 257:76-80.
63. Hakansson S, Caffrey M. Structural and dynamic properties of the HIV-1 tat transduction domain in the free and heparin-bound states. Biochemistry. 2003; 42:8999-9006.
64. Thoren PE, Persson D, Lincoln P, Norden B. Membrane destabilizing properties of cell-penetrating peptides. Biophys Chem. 2005; 114:169-179.
65. Kaplan IM, Wadia JS, Dowdy SF. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release. 2005; 102:247-253.
66. Su Y, Waring AJ, Ruchala P, Hong M. Membrane-bound dynamic structure of an arginine-rich cell-penetrating peptide, the protein transduction domain of HIV-Tat from solid-state NMR. Biochemistry. 2010; 49:6009-6020.
67. Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic Protein Transduction Domains: Enhanced Transduction Potential in vitro and in vivo. Cancer Res. 2001; 61:474-477